Please check your internet connection and try again.
# Miconazole Vaginal Pessary
## Overview
Miconazole is an imidazole antifungal agent.
## Primary Indications
Treatment of vulvovaginal candidiasis (yeast infection).
## Adult Dosing
* **100 mg vaginal suppository:** Insert one suppository vaginally at bedtime for 7 days.
* **200 mg vaginal suppository:** Insert one suppository vaginally at bedtime for 3 days.
* **100 mg vaginal cream:** Insert one applicatorful (approximately 5 grams) vaginally at bedtime for 7 days.
* **2% vaginal cream:** Insert one applicatorful (approximately 5 grams) vaginally at bedtime for 7 days.
* **200 mg vaginal suppository:** Insert one suppository vaginally at bedtime for 3 days.
* **4% vaginal cream:** Insert one applicatorful (approximately 5 grams) vaginally at bedtime for 3 days.
* **1200 mg vaginal suppository:** Insert one suppository vaginally as a single dose.
## Pediatric Dosing
Data is limited for pediatric patients. Dosing typically follows adult recommendations but should be guided by clinical judgment and available product labeling.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment.
## Contraindications
* Hypersensitivity to miconazole or any component of the formulation.
## Adverse Effects
* **Common:** Vulvovaginal burning, itching, irritation, abdominal cramps, pelvic pain.
* **Rare:** Rash, urticaria.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Substrates:** Miconazole is a potent inhibitor of CYP3A4. Concurrent use with warfarin may increase warfarin's anticoagulant effect. Concomitant use with other CYP3A4 substrates (e.g., certain statins, benzodiazepines, calcium channel blockers) may increase plasma concentrations of these drugs, potentially leading to toxicity.
* **Sirolimus, Tacrolimus, Cyclosporine:** Concomitant use may increase serum concentrations of these immunosuppressants.
## Monitoring
* Monitor for signs and symptoms of vulvovaginal candidiasis resolution.
* Assess for adverse effects, particularly local irritation and signs of systemic absorption.
* If co-administered with warfarin, monitor INR closely.
## Clinical Pearls
* Complete the full course of treatment as prescribed, even if symptoms improve.
* Avoid sexual intercourse during treatment.
* Patient education regarding proper insertion technique is important for efficacy.
* If symptoms persist or worsen after completing treatment, re-evaluate for alternative diagnoses or resistant organisms.
***
*This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information or a qualified healthcare provider for definitive guidance.*
